Details for Patent: 7,696,178

Title:	Optimised formulation of tobramycin for aerosolization
Abstract:	The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
Inventor(s):	Malvolti; Chiara (Parma, IT), Garzia; Raffaella (Parma, IT)
Assignee:	Chiesi Farmaceutici S.p.A. (Parma, IT)
Filing Date:	Mar 18, 2005
Application Number:	11/083,139
Claims:	1. An aerosol formulation, comprising: 75 mg/ml of tobramycin dissolved in an aqueous solution containing 0.45% w/v of sodium chloride; wherein the pH is between 4.5 and 5.5 and the osmolarity ranges between 250 and 450 mOsm/l, and said formulation is free of preservatives and anti-oxidants. 2. The aerosol formulation according to claim 1, wherein the pH is 5.2 and the osmolarity is between 280 and 350 mOsm/l. 3. A process for the preparation of an aerosol formulation according to claim 1, comprising: i) preparing an aqueous solution containing 0.45% w/v of sodium chloride; ii) adjusting the pH with a concentrated strong acid; iii) adding the active ingredient and mixing to complete dissolution; iv) re-adjusting the pH to the desired value; v) filling a suitable container with the solution. 4. The process according to claim 3, wherein the solution is pre-sterilized by filtration. 5. The aerosol formulation according to claim 1, wherein said osmolarity is 280 to 350 mOsm/l. 6. The process according to claim 3, wherein the concentrated strong acid is sulfuric acid. 7. The process according to claim 3, wherein in step ii) the pH is adjusted to 4.0 to 5.5. 8. The process according to claim 3, wherein in step iv) the pH is re-adjusted to 4.0 to 5.5. 9. The process according to claim 3, wherein said container is a multidose vial. 10. The process according to claim 3, wherein said container is a pre-sterilized unit vial of 2 ml. 11. The process according to claim 3, wherein said container is a pre-sterilized unit vial of 4 ml. 12. The process according to claim 3, wherein said filling in step v) is carried out under an inert atmosphere. 13. The aerosol formulation according to claim 1, which is stable for at least 9 months at room temperature. 14. An aerosol formulation, comprising 75 mg/ml of tobramycin dissolved in an aqueous solution containing 0.45% w/v of sodium chloride, wherein: the formulation has a pH of from 4.0 to 5.5; the formulation has an osmolarity of from 250 to 450 mOsm/l. 15. The aerosol formulation according to claim 1, wherein said osmolarity is 292 to 350 mOsm/l. 16. The aerosol formulation according to claim 1, wherein said osmolarity is 293 to 350 mOsm/l. 17. The aerosol formulation according to claim 1, wherein said osmolarity is 295 to 350 mOsm/l. 18. The aerosol formulation according to claim 1, wherein said osmolarity is 304 to 350 mOsm/l. 19. The aerosol formulation according to claim 1, wherein said osmolarity is 311 to 350 mOsm/l. 20. The aerosol formulation according to claim 1, wherein said osmolarity is 314 to 350 mOsm/l. 21. The aerosol formulation according to claim 14, wherein said osmolarity is 292 to 350 mOsm/l. 22. The aerosol formulation according to claim 14, wherein said osmolarity is 293 to 350 mOsm/l. 23. The aerosol formulation according to claim 14, wherein said osmolarity is 295 to 350 mOsm/l. 24. The aerosol formulation according to claim 14, wherein said osmolarity is 304 to 350 mOsm/l. 25. The aerosol formulation according to claim 14, wherein said osmolarity is 311 to 350 mOsm/l. 26. The aerosol formulation according to claim 14, wherein said osmolarity is 314 to 350 mOsm/l.